Brokerages expect Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Rating) to announce ($0.09) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Soleno Therapeutics’ earnings. Soleno Therapeutics posted earnings of ($0.11) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 18.2%. The business is scheduled to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Soleno Therapeutics will report full-year earnings of ($0.30) per share for the current fiscal year. For the next fiscal year, analysts forecast that the company will report earnings of ($0.20) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Soleno Therapeutics.
Soleno Therapeutics (NASDAQ:SLNO – Get Rating) last released its quarterly earnings results on Thursday, March 31st. The company reported ($0.08) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.08).
SLNO stock traded up $0.01 during midday trading on Tuesday, hitting $0.21. 911,059 shares of the stock traded hands, compared to its average volume of 571,149. The stock’s fifty day simple moving average is $0.27 and its 200-day simple moving average is $0.47. Soleno Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.67. The firm has a market cap of $16.50 million, a P/E ratio of -0.53 and a beta of 0.39.
Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. grew its position in shares of Soleno Therapeutics by 868.8% in the third quarter. BlackRock Inc. now owns 129,773 shares of the company’s stock valued at $120,000 after purchasing an additional 116,378 shares during the period. Granite Point Capital Management L.P. purchased a new stake in Soleno Therapeutics during the 3rd quarter valued at about $649,000. Geode Capital Management LLC raised its holdings in Soleno Therapeutics by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 430,253 shares of the company’s stock valued at $397,000 after acquiring an additional 18,185 shares during the last quarter. Two Sigma Investments LP lifted its stake in Soleno Therapeutics by 67.6% in the 3rd quarter. Two Sigma Investments LP now owns 365,846 shares of the company’s stock worth $338,000 after purchasing an additional 147,594 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Soleno Therapeutics during the 2nd quarter worth approximately $222,000. Institutional investors and hedge funds own 36.36% of the company’s stock.
Soleno Therapeutics Company Profile (Get Rating)
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program.
Read More
- Get a free copy of the StockNews.com research report on Soleno Therapeutics (SLNO)
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- The Sherwin-Williams Company Bottoms Above Institutional Support
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
- Whirlpool Is A Steal At These Prices
- Kimberly-Clark Pops On Successful Price Pass-Through
Get a free copy of the Zacks research report on Soleno Therapeutics (SLNO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
